Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reissued by Robert W. Baird in a report issued on Thursday. They currently have a $76.00 target price on the medical research company’s stock. Robert W. Baird’s price target suggests a potential upside of 5.28% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Tuesday, November 14th. Deutsche Bank set a $75.00 target price on Agilent Technologies and gave the company a “buy” rating in a research report on Tuesday, November 21st. Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 target price on shares of Agilent Technologies in a research report on Tuesday, September 26th. Cowen reiterated a “hold” rating and set a $70.00 target price on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Finally, Barclays lifted their target price on Agilent Technologies from $67.00 to $71.00 and gave the company an “overweight” rating in a research report on Tuesday, November 21st. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agilent Technologies has an average rating of “Buy” and an average price target of $69.25.

Agilent Technologies (A) traded up $0.13 during midday trading on Thursday, reaching $72.19. The company had a trading volume of 1,782,821 shares, compared to its average volume of 1,800,000. The stock has a market capitalization of $23,230.00, a P/E ratio of 34.54, a PEG ratio of 2.15 and a beta of 1.28. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37. Agilent Technologies has a 12 month low of $47.05 and a 12 month high of $72.50.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.05. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. Agilent Technologies’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 earnings per share. sell-side analysts anticipate that Agilent Technologies will post 2.58 earnings per share for the current fiscal year.

In other news, CEO Michael R. Mcmullen sold 22,481 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $70.00, for a total value of $1,573,670.00. Following the transaction, the chief executive officer now directly owns 327,882 shares in the company, valued at $22,951,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Didier Hirsch sold 12,964 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $69.00, for a total value of $894,516.00. Following the completion of the transaction, the chief financial officer now owns 184,851 shares in the company, valued at $12,754,719. The disclosure for this sale can be found here. Insiders sold 176,291 shares of company stock worth $12,245,920 over the last 90 days.

Several large investors have recently bought and sold shares of the stock. Advisor Group Inc. lifted its position in shares of Agilent Technologies by 0.3% in the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock worth $235,000 after buying an additional 10 shares in the last quarter. Veritable L.P. lifted its position in shares of Agilent Technologies by 0.4% in the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock worth $646,000 after buying an additional 40 shares in the last quarter. Balentine LLC lifted its position in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares in the last quarter. Kingfisher Capital LLC lifted its position in shares of Agilent Technologies by 0.3% in the second quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock worth $1,343,000 after buying an additional 58 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Agilent Technologies by 2.4% in the second quarter. Quadrant Capital Group LLC now owns 5,604 shares of the medical research company’s stock worth $317,000 after buying an additional 134 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/18/agilent-technologies-a-buy-rating-reiterated-at-robert-w-baird.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.